About Us

We know healthcare.

Our healthcare-focused angel investor group is comprised of accredited investors who are physicians, scientists, successful med-tech entrepreneurs, and experts with relevant backgrounds: regulatory, reimbursement, intellectual property & finance (private equity, venture capital, sovereign wealth funds).

Our notion of healthcare is quite liberal, so we will invest across sectors including: digital health, SaaS, medical devices, robotics, diagnostics, imaging, AI-driven technologies, and wellness (e.g. food/tech, sports/tech, media-promoting health).

For therapeutics, we limit investments to biosimilars and repurposed drugs. No first-in-humans.

We invest in Mid-Seed & Series A stage companies.

For those at the earlier Pre-Seed/Seed stages, we are also available to support your ventures in other ways: please check out our Advisory Program.

With many of our members active in the healthcare sector, MEDA Angels’ investments in technologies reflect not only strong market & technical validation of the products invested in, but members can often represent natural, prospective customers and impactful advisors to portfolio companies. We leverage our extensive networks to support companies in which we invest.

We are, thus, strategic investors.

Meet The Team


Elizabeth Cho-Fertikh, PhD
Co-Founder & Managing Director
  • 25 years drug development & clinical trials at biotechs & startups (oncology, infectious diseases, neurodegenerative diseases), regulatory affairs, grants administration & angel investing
  • ECF Biosolutions, Washington, DC
  • BA, Johns Hopkins University
  • PhD, Thomas Jefferson Medical School
  • Postdoctoral Fellowship, Harvard Medical School
Amir Rafii, MD
  • Head & Neck Surgery and Facial Plastic & Reconstructive Surgery, San Francisco Bay area
  • BS, University of California, Berkeley
  • MD, Georgetown Medical School
  • Residency, University of California, Davis
  • Fellowship, Virginia Mason Hospital
Ferdinand Hui, MD
  • Interventional Neuroradiology, Johns Hopkins Medical
  • Priors: Interventional Neuroradiology – Cleveland Clinic & Emory University Hosp
  • MD, University of VA Medical School
  • Residency, Medical College of VA
  • Fellowship, Emory University Hospital
Greg Buchert, MD, MPH
Executive Partner
  • Executive level roles in health plans & healthcare delivery systems
  • Former Pres & CEO, Blue Shield of CA’s Promise Health Plan
  • Former CEO, Centene’s Medicaid Managed Care Plan (CA)
  • Pediatric Emergency Care
  • BA, Tufts University
  • MD & MPH, Tulane School of Medicine
  • Residency, Tulane & Children’s Hospital of Oakland


Tai Mai, MBA
      • Digital health & AI technologies
      • BSE, Duke University, Biomedical Engineering
      • MBA, Georgetown McDonough School of Business


Lindsay DuRoss, MBA
      • Food Tech/Wellness/Media-Health
      • BA, Sarah Lawrence College
      • MBA, Rollins Crummer School of Business


Petrocelli Brooks, MBA
  • Managing Partner, Glen Echo Capital, focused on middle market & early stage healthcare, industrial & tech businesses
  • Former Merck & Pfizer exec: M&A, venture investments & strategic transactions
  • Former Goldman Sachs: healthcare investment banking
  • BS, Massachusetts Institute of Technology
  • MBA, Univ of Chicago Booth School of Business
John Brzezenski, MBA
  • 25+ years senior operating & exec management, advisory, private equity roles
  • Partner, J. Lock & Co, merchant bank
  • Angel investor & former Board Director, Launchpad Ventures,  since 2002
  • AB, Harvard University
  • MBA, Northwestern Kellogg School of Management
Edward E. Berger, Ph.D.
  • Reimbursement analysis, planning and advocacy
  • Healthcare public policy
  • Principal and Founder, Larchmont Strategic Advisors
  • Member, Mass Medical Angels
  • BA Harvard College
  • Ph.D. Boston University
Raj Malik
  • Partner, Pixel Perfect Ventures
  • 7 successful exits as leadership team member, founder or advisor
  • Helped scale Audax Health/Rally Health from pre-revenue to $1B in revenue, sold to UnitedHealth Group
  • CEO, Cofounder, Kikscore, sold to Google
  • Broad cross-functional experience in Operations, Corp Dev, Marketing/PR, Project/Mgmt roles
  • BA, Miami University 
  • JD, Ohio State University College of Law
Steven S. Brooks, MD, FACC
  • Interventional Cardiology
  • Nearly a decade at FDA, medical device 510K, de novo,  regulatory affairs
  • Principal, Brooks MedTech LLC, regulatory consulting
  • AB, Duke University
  • MD, University of Pittsburgh
  • MBA, Johns Hopkins Carey School of Business
  Alexander Antoniou, MD, MBA
  • Healthcare Investing, Reimbursements, Clinical Informatics, Nuclear Medicine
  • Venture Partner, FundRx
  • Priors: Director of Corporate Innovations, Carefirst Blue Cross Blue Shield; McKinsey & Co.
  • BS, Tufts University
  • MD, Tufts School of Medicine
  • MBA, Johns Hopkins Carey School of Medicine
  • House Staff, Nuclear Medicine, Johns Hopkins Hospital
Concetta Dudley, JD
  • Corporate counsel with 20+ yrs in Technology Commercialization
  • Advisor to startups & emerging companies
  • BA, Case Western Reserve University
  • JD, Cleveland State University
  • MA, Bioethics, University of Pennsylvania
Daniel Geselowitz, PhD
  • Angel Investor, Patent Agent specializing in biotech & chemical art, Kratz, Quintos & Hanson
  • BS, Haverford University
  • PhD, Stanford University
  • Postdoctoral Fellowship, University of North Carolina, Chapel Hill
Fred Gumbinner, JD
  • 30+ years micro private equity & angel investing
  • Managing Partner, G2 GEM Finance & ICON Finance
  • BA, Colgate University
  • JD, University of Michigan School of Law
   Nancy L. Cho, MD
  • Endocrine cancer surgery & cancer research, Brigham & Women’s Hospital & Harvard Medical School.
  • BS, Harvard University
  • MD, Columbia Medical School
  • Residency & Fellowship, Brigham & Women’s Hospital
James V. Ray
  • Twitter: Machine Learning Product Leader
  • Deep learning expert, data scientist (computer vision, natural language processing)
  • AI research and engineering leader
  • Corporate strategy executive
  • Formerly: Accenture, Deloitte
  • BA, Duke University
  • Duke’s Fuqua School of Business

For Investors

MEDA Angels provides Investor Members with several programs:

(1) Investment opportunities: this is our core program. We identify and screen promising deal flow sourced from throughout the US and on occasion, internationally. We present Mid-Seed and Series A investment opportunities, and where compelling, pre/Series B, in companies meeting our investment thesis (below, under “For Startups” section).

We strive to provide our members with the highest quality deal flow. How do we do this?

  • As actual potential end-users of novel healthcare technologies, we can expertly & swiftly assess the product market fit of technologies: a critical screening step.
  • We leverage our roots in and extensive networks built over years with top medical schools, healthcare systems, industry, research Centers of Excellence, incubators, accelerators and innovation hubs where many startups are spawn or affiliated with.
  • We exchange deal flow with trusted, syndicate partners who share the same vision & investment thesis.

(2) NEW! MEDA Angels Fund 1. All members have the opportunity to become investors (Limited Partners) in our inaugural Fund.  Closes Jan 31, 2023.

(3) Advisory opportunities: we recognize that some startups require a guiding hand, and with the right Advisory, can turn into rising stars. As senior-level experts, our Members are positioned to be such Advisors. Our twice-a-year Startup Showcases are intended to introduce startups to Advisors/Investors. Program details are provided here.

(4) Education: our sessions are often a unique blend of Investor Roundtables meet Medical Grand Rounds, bringing both sides of the table together on:

  • Macro & healthcare-specific investment topics.
  • Healthcare domain-specific topics, including reimbursement, telehealth, hospital value add committees, AI in health.
  • Current topics, such as value-based care, telehealth, COVID-19.
  • Due diligence, terms sheets, cap tables.

We  meet every month, virtually and occasionally, in person.

We invite accredited investors to join as members! To check whether you qualify for accredited investor status per the U.S. Securities & Exchange Commission regulations, CLICK HERE .

Click here to learn more about our memberships.

learn more

For Startups

Welcome entrepreneurs! We’d love to learn more about your technology or product. We invest in Mid-Seed and Series A-ready companies, with a preference for equity investment opportunities. If yours meets these criteria and those described below, please apply by submitting a pitch deck and executive summary. We will conduct an initial screening and reach out with a decision. If selected, we will be pleased to extend an invitation to present to our members! Thank you for your interest in MEDA Angels.


  • Geography: Companies based anywhere in the US. Non-US-based companies: should have some type of US presence, whether a subsidiary, key staff or Board members in the US.  Limited tax complexities for US investors.  Please inquire.
  • Mid Seed minimum criteria:
    • Digital health/SaaS: $300K+ in annual recurring revenue
    • Non-invasive medical devices/techs: preclinical testing including toxicology completed.  approx 2-8 months from 510K submission.
    • Invasive medical devices/techs: FDA 510K or de novo approved and/or CE mark.
    • Therapeutics: No first-in-human drugs. Biosimilars & repurposed drugs considered. IND or 505(b)(2) approved or comparable regulatory status if non-US company.
  • Series A criteria:  more advanced than mid-seed.  Flexible on how advanced.  Please inquire.
apply now

The Apply Now link will take you to sparkxyz.io, our application platform.